Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.280 -0.290 (-5.21%)
Streaming Delayed Price Updated: 3:48 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023
CADL stock results show that Candel Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Recap: Candel Therapeutics Q4 Earnings
Via Benzinga
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies
--News Direct-- 
Via News Direct
Recap: Candel Therapeutics Q3 Earnings
Via Benzinga
Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors
--News Direct-- 
Via News Direct
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END 
Via FinancialNewsMedia
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
From Candel Therapeutics
Via GlobeNewswire
Moving Fast: Candel’s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer
--News Direct-- 
Via News Direct
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies
A clinical-stage biopharmaceutical company looks forward to the year ahead with several promising developments in motion.  
Via Benzinga
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
From Candel Therapeutics
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
US Stocks Edge Lower; Inflation Rate Slows to 3.1% In November
U.S. stocks traded slightly lower this morning, following the release of inflation data on Tuesday. Following the market opening Tuesday, the Dow traded down 0.04% to 36,389.01 while the NASDAQ fell... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Why Is Cancer Player Candel Therapeutics Stock Trading Higher Today?
Candel Therapeutics Inc (NASDAQ: CADL) released initial interim survival and immunological biomarker data from the ongoing phase 2 trial of CAN-2409 plus valacyclovir (prodrug) together with standard... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
From Candel Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.